Chylothorax after surgery for congenital heart disease

Maria T. Zuluaga

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose of Review: Postoperative chylothorax is a frequently encountered pathology in the cardiac intensive care unit. The continuous loss of chyle is a challenging problem to treat and is associated with increased morbidity and mortality. The purpose of this article is to review the pathophysiology of chylothorax in patients after surgery for congenital heart disease, its implications and the current therapies available. Recent Findings: The incidence of chylothorax has been increasing over the last two decades. Multiple uncontrolled case series describe octreotide as an effective treatment, and octreotide usage is increasing around the world for patients nonresponsive to dietary modifications. Most centers reserve surgical treatment for patients nonresponsive after 4 weeks of medical treatment. Less-invasive surgical procedures such as thoracic duct ligation by video-assisted thoracoscopy are gaining popularity. Summary: Chylothorax is commonly seen in children after surgery for congenital heart disease. The multiple and serious complications associated with chylous effusions are well known. Conservative therapy with diet modification and octreotide remain the standard initial approach. Thoracic duct ligation has been reported as a highly successful treatment but has considerable risk. Thus, this procedure should be reserved for patients nonresponsive to conservative therapy.

Original languageEnglish (US)
Pages (from-to)291-294
Number of pages4
JournalCurrent Opinion in Pediatrics
Volume24
Issue number3
DOIs
StatePublished - Jun 2012

Fingerprint

Chylothorax
Heart Diseases
Octreotide
Diet Therapy
Thoracic Duct
Ligation
Chyle
Therapeutics
Thoracoscopy
Intensive Care Units
Pathology
Morbidity
Mortality
Incidence

Keywords

  • chylothorax
  • congenital heart disease
  • octreotide

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Chylothorax after surgery for congenital heart disease. / Zuluaga, Maria T.

In: Current Opinion in Pediatrics, Vol. 24, No. 3, 06.2012, p. 291-294.

Research output: Contribution to journalArticle

Zuluaga, Maria T. / Chylothorax after surgery for congenital heart disease. In: Current Opinion in Pediatrics. 2012 ; Vol. 24, No. 3. pp. 291-294.
@article{a44007a14b774876b9977379bcfa6412,
title = "Chylothorax after surgery for congenital heart disease",
abstract = "Purpose of Review: Postoperative chylothorax is a frequently encountered pathology in the cardiac intensive care unit. The continuous loss of chyle is a challenging problem to treat and is associated with increased morbidity and mortality. The purpose of this article is to review the pathophysiology of chylothorax in patients after surgery for congenital heart disease, its implications and the current therapies available. Recent Findings: The incidence of chylothorax has been increasing over the last two decades. Multiple uncontrolled case series describe octreotide as an effective treatment, and octreotide usage is increasing around the world for patients nonresponsive to dietary modifications. Most centers reserve surgical treatment for patients nonresponsive after 4 weeks of medical treatment. Less-invasive surgical procedures such as thoracic duct ligation by video-assisted thoracoscopy are gaining popularity. Summary: Chylothorax is commonly seen in children after surgery for congenital heart disease. The multiple and serious complications associated with chylous effusions are well known. Conservative therapy with diet modification and octreotide remain the standard initial approach. Thoracic duct ligation has been reported as a highly successful treatment but has considerable risk. Thus, this procedure should be reserved for patients nonresponsive to conservative therapy.",
keywords = "chylothorax, congenital heart disease, octreotide",
author = "Zuluaga, {Maria T.}",
year = "2012",
month = "6",
doi = "10.1097/MOP.0b013e3283534b7f",
language = "English (US)",
volume = "24",
pages = "291--294",
journal = "Current Opinion in Pediatrics",
issn = "1040-8703",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Chylothorax after surgery for congenital heart disease

AU - Zuluaga, Maria T.

PY - 2012/6

Y1 - 2012/6

N2 - Purpose of Review: Postoperative chylothorax is a frequently encountered pathology in the cardiac intensive care unit. The continuous loss of chyle is a challenging problem to treat and is associated with increased morbidity and mortality. The purpose of this article is to review the pathophysiology of chylothorax in patients after surgery for congenital heart disease, its implications and the current therapies available. Recent Findings: The incidence of chylothorax has been increasing over the last two decades. Multiple uncontrolled case series describe octreotide as an effective treatment, and octreotide usage is increasing around the world for patients nonresponsive to dietary modifications. Most centers reserve surgical treatment for patients nonresponsive after 4 weeks of medical treatment. Less-invasive surgical procedures such as thoracic duct ligation by video-assisted thoracoscopy are gaining popularity. Summary: Chylothorax is commonly seen in children after surgery for congenital heart disease. The multiple and serious complications associated with chylous effusions are well known. Conservative therapy with diet modification and octreotide remain the standard initial approach. Thoracic duct ligation has been reported as a highly successful treatment but has considerable risk. Thus, this procedure should be reserved for patients nonresponsive to conservative therapy.

AB - Purpose of Review: Postoperative chylothorax is a frequently encountered pathology in the cardiac intensive care unit. The continuous loss of chyle is a challenging problem to treat and is associated with increased morbidity and mortality. The purpose of this article is to review the pathophysiology of chylothorax in patients after surgery for congenital heart disease, its implications and the current therapies available. Recent Findings: The incidence of chylothorax has been increasing over the last two decades. Multiple uncontrolled case series describe octreotide as an effective treatment, and octreotide usage is increasing around the world for patients nonresponsive to dietary modifications. Most centers reserve surgical treatment for patients nonresponsive after 4 weeks of medical treatment. Less-invasive surgical procedures such as thoracic duct ligation by video-assisted thoracoscopy are gaining popularity. Summary: Chylothorax is commonly seen in children after surgery for congenital heart disease. The multiple and serious complications associated with chylous effusions are well known. Conservative therapy with diet modification and octreotide remain the standard initial approach. Thoracic duct ligation has been reported as a highly successful treatment but has considerable risk. Thus, this procedure should be reserved for patients nonresponsive to conservative therapy.

KW - chylothorax

KW - congenital heart disease

KW - octreotide

UR - http://www.scopus.com/inward/record.url?scp=84861092102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861092102&partnerID=8YFLogxK

U2 - 10.1097/MOP.0b013e3283534b7f

DO - 10.1097/MOP.0b013e3283534b7f

M3 - Article

C2 - 22498675

AN - SCOPUS:84861092102

VL - 24

SP - 291

EP - 294

JO - Current Opinion in Pediatrics

JF - Current Opinion in Pediatrics

SN - 1040-8703

IS - 3

ER -